Viridian Therapeutics

Biotech & Life Sciences · Boulder, United States · Founded 2007 · IPO 2017

Focused on the development therapeutics for the treatment of cardiovascular and muscle diseases MoreLess

Viridian Therapeutics is a biopharmaceutical company that discovers and develops microRNA (miRNA)-targeting therapies. The company is focused on developing innovative therapies for thyroid eye disease through advanced monoclonal antibody technology targeting the IGF-1R pathway.

Viridian Therapeutics operates in the biopharmaceutical market, specifically focusing on rare autoimmune diseases. Its clients are patients suffering from these conditions. The company's business model revolves around the discovery, development, and subsequent commercialization of novel treatments. As a clinical-stage biopharmaceutical company, its revenue generation will likely depend on the successful approval and market launch of its therapeutic candidates.

Keywords: biopharmaceutical, microRNA, antibody engineering, autoimmune diseases, thyroid eye disease, monoclonal antibody, IGF-1R, rare diseases, clinical-stage, drug development

Valuation $1.44B

Revenue $71M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Knowledge graph

News Viridian Therapeutics raises $350M in upsized dual public offerings Jun 3, 2026

Talent graph

Viridian Therapeutics's talent

Book a demo to see the people

Employees mapped 278 incl. 1 AI specialist

Founders /100 quality score

Key operators 18 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

13 investors on Viridian Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage

Boulder Ventures

Atlas Venture

Broadview Ventures

Amgen Ventures

Remeditex Ventures

Series B+ 8 investors entered at this stage

MP Healthcare Venture Management

JAFCO

Brace Pharma

MRL Ventures

Fidelity Investments

Hercules Capital

Braidwell

DRI Healthcare

Global footprint

Where Viridian Therapeutics has talent and traffic

Workforce by country

6 countries with
team presence

🇺🇸 United States98.2%

🇫🇷 France0.3%

🇦🇹 Austria0.3%

🇰🇼 Kuwait0.3%

🇬🇧 United Kingdom0.3%

Top 5 of 6 shown

Web traffic by country

17K monthly visits
across markets

🇺🇸 United States47.6%

🇨🇦 Canada25.3%

🇮🇳 India10.6%

🇬🇧 United Kingdom5.9%

🇵🇭 Philippines2.9%

Top 5 markets shown

Patent intelligence

$59M patent portfolio · 32 active families

Estimated portfolio value

$59M

4.1% of market cap · 1.6× smaller than top peer WuXi Biologics ($95M)

32 active patent families

Where Viridian Therapeutics innovates Antiendomysial antibodiesBiologyDiseaseEye diseaseMedicinal chemistry

Where Viridian Therapeutics concentrates vs peers

Each axis is a top-10 topic across Viridian Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Viridian Therapeutics

An AI-synthesized read of the highest-engagement posts about Viridian Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Viridian Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles